Trial · NCT00620555
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | All-causality adverse events (AEs) | 58 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Treatment-related AEs | 13 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | All-causality serious AEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Treatment-related serious AEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | All-causality severe AEs | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Treatment-related severe AEs | 0 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Discontinuation due to all-causality AEs | 4 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Discontinuation due to treatment-related AEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Dose reduction due to all-causality AEs | 2 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (All Causalities and Treatment-Related) | Gabapentin | Dose reduction due to treatment-related AEs | 2 | Participants | |
| Response Ratio | Gabapentin | Week 1 to 8 (n=65) | -0.263 | Standard Deviation 0.3141 | Ratio |
| Response Ratio | Gabapentin | Week 9 to 16 (n=60) | -0.256 | Standard Deviation 0.3513 | Ratio |
| Response Ratio | Gabapentin | Week 17 to 24 (n=58) | -0.300 | Standard Deviation 0.3671 | Ratio |
| Response Ratio | Gabapentin | Week 25 to 36 (n=54) | -0.280 | Standard Deviation 0.3753 | Ratio |
| Response Ratio | Gabapentin | Week 37 to 52 (n=47) | -0.327 | Standard Deviation 0.3712 | Ratio |
| Responder Rate | Gabapentin | Week 1 to 8 (n=65) | 35.4 | 95% Confidence Interval 23.9 to 48.2 | Percentage of participants |
| Responder Rate | Gabapentin | Week 9 to 16 (n=60) | 40.0 | 95% Confidence Interval 27.6 to 53.5 | Percentage of participants |
| Responder Rate | Gabapentin | Week 17 to 24 (n=58) | 39.7 | 95% Confidence Interval 27.1 to 53.4 | Percentage of participants |
| Responder Rate | Gabapentin | Week 25 to 36 (n=54) | 40.7 | 95% Confidence Interval 27.6 to 55.0 | Percentage of participants |
| Responder Rate | Gabapentin | Week 37 to 52 (n=47) | 46.8 | 95% Confidence Interval 32.1 to 61.9 | Percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00620555/results